ArticleJournal of empirical research on human research ethics : JERHRE2014
Ancillary care in South African HIV vaccine trials: addressing needs, drafting protocols, and engaging community.
Article in Journal of empirical research on human research ethics : JERHRE, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- An ancillary care policy in a vaccine trial conducted in a resource-constrained setting: evaluation and policy recommendations.BMJ global health · 2024Trial
- Standard of prevention for infectious diseases' prevention clinical trials during pandemics: learning lessons for global policies from biomedical HIV prevention clinical trials and a case study of COVID-19.Frontiers in public health · 2024Article
- 'Guidance should have been there 15 years ago' research stakeholders' perspectives on ancillary care in the global south: a case study of Malawi.BMC medical ethics · 2023Article
- Facilitated transition in HIV drug trial closure: A conceptual model for HIV post-trial care.PloS one · 2021Article
- The ethical imperative to treat NCDs during research in Africa.The Lancet. Global health · 2019Article
- Strengthening stakeholder engagement through ethics review in biomedical HIV prevention trials: opportunities and complexities.Journal of the International AIDS Society · 2018Review
- New ethical considerations in vaccine trials.Human vaccines & immunotherapeutics · 2017Article
- Ensuring Access to HIV Prevention Services in South African HIV Vaccine Trials: Correspondence Between Guidelines and Practices.Public health ethics · 2014Article
- Stakeholder views of ethical guidance regarding prevention and care in HIV vaccine trials.BMC medical ethics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
There has been debate about sponsor-investigator ethical responsibilities to address participants' medical needs in trials in resource-constrained contexts. Certain ethical guidelines make detailed recommendations. This study explored whether ethical guideline recommendations for care in HIV vaccine trials were being met, and whether stakeholders were facing difficulties addressed by guidelines. It sampled key stakeholders involved in two trials across five sites in South Africa, and reviewed relevant documentation. It concluded that sites were largely meeting guideline recommendations for addressing needs, with some exceeding these. Recommendations for writing protocols were only partially achieved. Recommendations for engaging participating community were mostly met, except for "moral negotiation" recommendations. Suggestions are made to strengthen practices, and to improve guidelines so they address empirical concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.